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Background: Low levels of serum adiponectin have been linked to central obesity, insulin resistance, metabolic
syndrome, and type 2 diabetes. Variants in ADIPOQ, the gene encoding adiponectin, have been shown to influence
serum adiponectin concentration, and along with variants in the adiponectin receptors (ADIPOR1 and ADIPOR2)
have been implicated in metabolic syndrome and type 2 diabetes. This study aimed to comprehensively investigate
the association of common variants in ADIPOQ, ADIPOR1 and ADIPOR2 with serum adiponectin and insulin
resistance syndromes in a large cohort of European-Australian individuals.
Methods: Sixty-four tagging single nucleotide polymorphisms in ADIPOQ, ADIPOR1 and ADIPOR2 were genotyped
in two general population cohorts consisting of 2,355 subjects, and one cohort of 967 subjects with type 2
diabetes. The association of tagSNPs with outcomes were evaluated using linear or logistic modelling. Meta-analysis
of the three cohorts was performed by random-effects modelling.
Results: Meta-analysis revealed nine genotyped tagSNPs in ADIPOQ significantly associated with serum adiponectin
across all cohorts after adjustment for age, gender and BMI, including rs10937273, rs12637534, rs1648707,
rs16861209, rs822395, rs17366568, rs3774261, rs6444175 and rs17373414. The results of haplotype-based analyses
were also consistent. Overall, the variants in the ADIPOQ gene explained <5% of the variance in serum adiponectin
concentration. None of the ADIPOR1/R2 tagSNPs were associated with serum adiponectin. There was no association
between any of the genetic variants and insulin resistance or metabolic syndrome. A multi-SNP genotypic risk score
for ADIPOQ alleles revealed an association with 3 independent SNPs, rs12637534, rs16861209, rs17366568 and type
2 diabetes after adjusting for adiponectin levels (OR=0.86, 95% CI=(0.75, 0.99), P=0.0134).
Conclusions: Genetic variation in ADIPOQ, but not its receptors, was associated with altered serum adiponectin.
However, genetic variation in ADIPOQ and its receptors does not appear to contribute to the risk of insulin
resistance or metabolic syndrome but did for type 2 diabetes in a European-Australian population.
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Adiponectin is the most abundant adipose tissue-derived
cytokine. It has anti-inflammatory, anti-diabetic and anti-
atherogenic properties, and low circulating levels are
associated with central obesity, insulin resistance, meta-
bolic syndrome (MetS), and type 2 diabetes (T2D) [1].
Serum adiponectin concentrations are highly heritable,
and a number of genome-wide association studies (GWAS)
have identified ADIPOQ, the gene encoding adiponectin,
as the main locus contributing to variations in serum levels
in European and Asian populations [2-5]. Cross-sectional
studies in healthy and diabetic populations have provided
further evidence for the association of single nucleotide
polymorphisms (SNPs) in ADIPOQ with serum adipo-
nectin concentrations [6-10]. Several studies have linked
ADIPOQ variants to T2D and MetS, although the results
to date have been discordant and not replicated across
whole populations [5,8-12]. Nevertheless, examining the
genes which affect serum adiponectin levels may help to
confirm adiponectin as a cause or consequence of MetS
and T2D using a Mendelian randomisation approach [13].
Adiponectin cellular signalling is mediated by two
adiponectin receptors. The genes for these (ADIPOR1
and ADIPOR2), although generally not associated with
serum adiponectin, have themselves been implicated in
insulin resistance and T2D risk in genetic association
studies, but also with inconsistent results [14-18].
In light of this background, the aims of the present study
were i) to examine the evidence for association between
total serum adiponectin levels and variants in ADIPOQ
and ADIPOR1/R2 using a comprehensive tagSNP approach
and haplotype-based analysis, ii) to assess associations be-
tween SNPs in these genes and total serum adiponectin
concentrations in large, well-characterised and independ-
ent Western Australian cohorts (two general population
and one adult T2D cohort), and iii) to investigate the rela-
tionship between gene variants found to be associated with




This study examined subjects from threeWesternAustralian
cohorts: the Busselton Population Health Survey (BHS) [19],
the Carotid Ultrasound Disease Assessment Study (CUDAS)
[20] and the Fremantle Diabetes Study (FDS) [21].
The BHS and CUDAS cohorts are representative of
the general population and do not contain individuals
with T2D, while FDS contains individuals with T2D who
are representative of people with diabetes in an urban
Australian setting. These cohorts are predominantly
European-Australian. The present study was restricted
to individuals who had both serum adiponectin and
genotyping data available.The subset of the BHS cohort with available data
consisted of 1,322 unrelated adult individuals who were
recruited as part of a larger cross-sectional community
study in 1994/1995 [22]. The CUDAS cohort comprised
1,033 individuals selected from a random electoral survey
from the Perth metropolitan area [20]. The FDS cohort
of 967 diabetic individuals was recruited from a longitu-
dinal observational study [21]. All study participants gave
written informed consent, and the study protocol was
approved by the University of Western Australia Human
Research Ethics Committee, the Busselton Population
Medical Research Foundation, and the Human Rights
Committee at Fremantle Hospital.
Biochemical and anthropomorphic analyses
A fasting blood sample was obtained from each subject.
Total serum adiponectin levels were measured by a
commercially available quantitative sandwich enzyme im-
munoassay technique (R&D Systems Inc., Minneapolis,
Minnesota, USA). The intra-assay coefficients of variation
ranged from 2.1 to 4.3% and the inter-assay coefficients of
variation ranged from 5.4 to 9.6%. Plasma glucose, insulin,
total cholesterol, LDL- and HDL-cholesterol, and trigly-
cerides were determined by standard methods [19-21]. In-
sulin resistance (IR) was determined using the homeostatic
model of assessment scores (lnHOMA-IR) [23]. Anthropo-
metric measurements and resting blood pressure were
taken according to standard clinical procedures. Body mass
index (BMI) was calculated as weight (kg)/height (m)2.
Metabolic syndrome (MetS) was defined according to the
recently updated National Cholesterol Education Program
(NCEP) criteria [24]. Individuals with three or more of the
following criteria were classified as having MetS: increased
waist circumference (≥102 cm in men, ≥88 cm in women),
hypertriglyceridaemia ≥1.70 mmol/L (≥150 mg/dL), low
HDL-cholesterol <1.00 mmol/L in men and <1.3 mmol/L
in women (<40 mg/dL and <50 mg/dL), high blood pres-
sure (systolic ≥130 and/or diastolic ≥85 mm Hg, or current
use of antihypertensive therapy) and high fasting glucose
≥5.6 mmol/L (≥100 mg/dL). Data for clinical and demo-
graphic characteristics (Table 1) are given as proportions,
mean±SD, or geometric mean (SD range).
Selection and genotyping of tSNPs
A tagSNP (tSNP) approach (r2≥0.80, minor allele frequency
≥5%) was used to explore the genetic variation in ADIPOQ,
ADIPOR1, and ADIPOR2. tSNPs were selected using
Haploview to represent the common genetic variation of
each gene, including an additional 10 kb upstream and
downstream, as well as variants previously reported in the
literature to be associated with serum adiponectin levels.
Sixty-four tSNPs in ADIPOQ (8), ADIPOR1 and ADIPOR2
(15, 16) were selected and genotyped based on this ap-
proach (Additional file 1). Genotyping was performed on
Table 1 Baseline clinical, metabolic, and demographic characteristics of each cohort by gender
BHS CUDAS FDS
Female (n=736) Male (n=586) Female (n=521) Male (n=512) Female (n=489) Male (n=478)
Adiponectin (mg/L) 14.2 (8.1–24.8) 7.9 (4.2–15.0) 13.9 (8.1–23.8) 7.9 (4.5–14.0) 8.6 (4.4–16.6) 5.9 (3.0–11.4)
Age (years) 51.3±17.8 51.5±17.7 52.8±12.7 53.2±12.8 64.6±11.4 64.4±10.3
SBP (mm Hg) 122±20 126±16 126±20 129±16 150±23 151±23
DBP (mm Hg) 73±10 77±10 78±11 82±9 79±11 83±11
Fasting Glucose (mmol/L) 4.8±0.5 4.9±0.5 5.3±0.7 5.3±0.8 8.7 (6.3–12.0) 8.6 (6.2–11.8)
Fasting Insulin (IU/L)* 41.6 (24.6–70.3) 44.6 (24.6–80.8) 33.6 (18.4–61.4) 36.1 (19.1–68.5) 80.7 (44.2–147.2) 68.0 (34.6–133.4)
lnHOMA-IR (insulin resistance) 0.9 (0.5–1.5) 0.9 (0.5–1.7) 0.6 (0.3–1.2) 0.7 (0.4–1.3) 1.7 (0.9–3.2) 1.4 (0.7–2.8)
Total cholesterol (mmol/L) 5.6±1.2 5.5±1.0 5.6±1.0 5.5±1.0 5.7±1.1 5.2±1.1
LDL-cholesterol (mmol/L) 3.5±1.0 3.7±0.9 3.6±0.9 3.7±0.9 3.6±1.0 3.3±0.8
HDL-cholesterol (mmol/L) 1.51 (1.17–1.95) 1.18 (0.91–1.54) 1.47 (1.14–1.88) 1.14 (0.89–1.47) 1.09 (0.82–1.46) 0.93 (0.68–1.26)
Serum triglycerides (mmol/L) 1.0 (0.6–1.7) 1.2 (0.7–2.2) 1.0 (0.6–1.6) 1.2 (0.7–2.1) 1.9 (1.2–3.0) 1.9 (1.0–3.4)
Body Mass Index (BMI) (kg/m2) 25.1±4.4 26.3±3.5 25.3±4.4 26.6±3.5 30.2±5.9 28.9±4.5
Waist circumference (cm) 79.7±11.0 92.9±10.2 76.9±10.4 92.0±9.2 96.4±12.6 103.4±11.2
Waist-Hip ratio 0.79±0.06 0.93±0.06 0.76±0.06 0.90±0.05 0.86±0.06 0.96±0.06
Antihypertensive tx (%) 19.2 16.1 13.8 13.9 56.4 45.4
Smoking (never/ex/current) (%) 60.2/28.9/10.9 47.6/37.1/15.2 62.8/24.2/13.1 39.1/43.6/17.4 64.4/23.6/12.0 24.9/57.4/17.6
NCEP_Hypertension (%) 40.0 46.2 47.0 54.7 92.8 91.0
NCEP_Hyperglycaemia (%) 7.1 10.0 33.9 40.2 94.3 93.5
NCEP_Hypertriglyceridemia (%) 17.4 28.9 14.8 30.7 59.0 58.7
NCEP_LowHDL (%) 27.3 26.8 30.1 29.3 73.1 60.0
NCEP_Obese (%) 20.7 18.1 16.3 14.8 74.1 55.0
NCEP_MetSScore† (%)
0 39.8 31.7 27.2 18.6 0.4 0.2
1 29.9 32.3 29.5 27.1 1.0 2.0
2 16.6 18.3 26.4 29.6 8.5 15.8
3+ 13.7 17.7 17.0 24.7 90.0 82.0
* insulin in non-insulin users † NCEP_MetSScore is the number of MetS components.
The data for continuous variables is mean±standard deviation, or geometic mean (standard deviation range). The data for categorical variables is shown
as proportions.
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DNA samples from CEPH trios (obtained from the Coriell
Cell Repository) served as internal controls for quality of
clustering and reproducibility. A random (10%) sample was
analysed in duplicate, with reproducibility found to be
100% for the Busselton population and 99.9% for both
CUDAS and FDS populations. Individual SNP concordance
rates were between 99.3 and 100%. Deviations fromHardy–
Weinberg equilibrium (HWE) (P<0.05) were examined for
each tSNP using Fisher’s exact test, and minor allele fre-
quencies determined for each cohort.
Analysis of association between tSNPs and adiponectin
levels
Adiponectin levels were normalised using a natural lo-
garithm transformation prior to analysis. Associationsbetween transformed values and genotypes at each tSNP
were examined using a generalised linear model approach
implemented in SimHap [25]. Each polymorphism was
modelled as a genotypic (codominant) genetic effect, ac-
commodating the effects of age, gender, and BMI as sig-
nificant covariates. We determined marginal geometric
mean values of adiponectin according to genotype at each
tSNP using SimHap. We corrected for the multiple testing
inherent in this study using the false discovery rate
method, and provide q-values [26] (Additional file 2). Sta-
tistical significance was defined at α<0.05.
We used Haploview [27] to determine the linkage dis-
equilibrium (LD) between the selected tSNPs and charac-
terise the haplotype block structure. Haplotypes were
inferred for individuals with ambiguous phase and haplo-
type frequencies were estimated using an expectation–
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Haplotypes were recorded as independent factors into
three classes (0, 1, or 2), representing the number of cop-
ies of each haplotype in an individual’s diplotype. The
effect of each individual haplotype was calculated relative
to not having that haplotype. To investigate associations
with serum adiponectin, common haplotypes (frequency
>5%) were examined using a codominant model adjusted
for age, gender and BMI (Additional file 3).
Meta-analysis of the ADIPOQ polymorphisms against
total serum adiponectin in the three cohorts was carried
out using the rmeta package in R version 2.8.0. All three
cohorts were pooled after checking for genetic hetero-
geneity for each tSNP. Random-effects modelling were
used for the meta-analysis as we assumed that the cohorts
would be heterogeneous.
Analysis of association between tSNPs and T2D, lnHOMA-
IR and MetS
Associations between tSNPs and T2D, log transformed
HOMA-IR (lnHOMA-IR) and MetS were evaluated in
SimHap using a codominant model corrected for age,
gender and BMI. For T2D, the FDS cohort was compared
to control individuals without a history of diabetes from
the combined BHS and CUDAS cohorts. LnHOMA-IR
was modelled as a quantitative outcome, while MetS was
analysed as an ordinal outcome in the BHS and CUDAS
cohorts for the number of MetS criteria met. In addition
to investigating the tSNPs independently, an allele score
was created by summing the number of risk alleles an
individual had in those tSNPs that were shown to be
associated with adiponectin levels in the meta-analysis.
Power analysis
A power calculation, performed in the Quanto software
[28], indicated that this study has at least 90% power at
an alpha level of p=0.05 to detect an odds ratio for dia-
betes (population risk of 10%) of 1.45 for a minor allele
frequency of 0.05 and an odds ratio of 1.2 for a minor al-
lele frequency of 0.45, under an additive genetic model.
Results
Sample characteristics
A total of 3,322 subjects from the three cohorts were
included (Table 1). As expected, the two general population-
based cohorts differed significantly to the diabetic cohort in
cardiometabolic risk characteristics, reflecting the different
recruitment criteria. The BHS andCUDAS populations were
similar with regards serum adiponectin concentrations, age
and BMI. Compared with the BHS and CUDAS cohorts, the
FDS population was older, had lower serum adiponectin
concentrations, and had higher BMI and systolic blood
pressure. In all three cohorts, females had higher serum
adiponectin concentrations thanmales.Genotype distribution and linkage disequilibrium
Of the sixty-four genotyped tSNPs, five failed and six were
monomorphic, leaving fifty-three that were included in the
association analyses (21 in ADIPOQ, 13 in ADIPOR1, and
19 in ADIPOR2). Details of these tSNPs including genotype
and allele frequencies are reported in Additional file 1. Al-
lele frequencies for all tSNPs were similar to those reported
in HapMap (http://hapmap.ncbi.nlm.nih.gov/). The geno-
type distribution of each tSNP was consistent with HWE in
all populations, with the following exceptions: two tSNPs in
BHS (ADIPOR1 rs75114693 and ADIPOR1 rs6666089) and
one tSNP in CUDAS (ADIPOR1 rs6666089) (all P<0.05).
Analysis of pairwise LD in ADIPOQ showed three LD
blocks (Figure 1), which were similar between all three
cohorts. Haplotypes were analysed within each block for
association with the outcomes of interest. A strong cor-
relation (D’>0.90 and r2>0.8) was found between tSNPs
rs6810075 and rs1648707, rs864265 and rs860291,
rs822387 and rs16861209, rs822391 and rs822396, and
rs2241766 and rs1063537 within each cohort. Statistical
analysis showed that the effects of each of these tSNP
pairs on adiponectin levels were identical, and for this
reason we chose to report on only one tSNP from each
pair: rs1648707, rs860291, rs16861209, rs822396 and
rs1063537. There was no interaction between gender
and any of the genetic variants, so males and females
were combined for all subsequent analyses.
Association of single tSNPs with serum adiponectin
Age, gender and BMI accounted for 35.5% of the variation
in serum adiponectin in the BHS cohort, 33.2% in
CUDAS, and 22.0% in FDS. After adjustment for these
covariates and, under a codominant model, eight tSNPs
in ADIPOQ were significantly associated with serum
adiponectin in the BHS cohort: rs12637534, rs1648707,
rs16861209, rs17366568, rs3774261, rs1063537, rs6444175
and rs17373414 (all q<0.05). Of these, four were signifi-
cant in CUDAS (rs1648707, rs16861209, rs3774261, and
rs6444175), and two in FDS (rs16861209 and rs17366568).
Full results (for these eight SNPs) for each cohort, inclu-
ding the data for tSNPs in LD, are shown in Additional file
2. None of the tSNPs in ADIPOR1/R2 were associated
with serum adiponectin in any of the cohorts.
After adjustment for age, gender and BMI, tSNPs
rs12637534, rs16861209 and rs17366568 accounted for 4.8%
of the variance in serum adiponectin in BHS, rs1648707 and
rs16861209 explained 2.9% of the variance in CUDAS, and
rs16861209 and rs17366568 accounted for 1.7% in FDS.
The minor allele at rs16861209 (A allele) was consistently
associated with increased serum adiponectin across all three
cohorts, specifically 3.7 mg/L in BHS, 2.7 mg/L in CUDAS
and 1.3 mg/L in FDS (Additional file 2).
Meta-analysis of all ADIPOQ tSNPs in our three
cohorts is shown in Table 2. tSNPs in LD gave identical
Exon 1 Exon 2 Exon 3 
3kcolB2kcolB1kcolB
Chr3
Figure 1 Linkage disequilibrium plot of SNPs within ADIPOQ using data from the combined BHS/CUDAS cohorts. Schematic
representation of the adiponectin (ADIPOQ) gene on chromosome 3. The exon/intron structure of the gene is shown, together with the pairwise
linkage disequilibrium (LD) and haplotype blocks across the gene. The protein coding region is shown by black shading in exons 2 and 3. The D’
values for each SNP pair are shown, with dark red diamonds without a corresponding D’ value representing complete LD (D’=1).
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presented. As FDS displayed different mean levels of
adiponectin and other quantative traits, a second meta-
analysis was conducted without the FDS study and simi-
lar results were found (data not shown).
The meta-analysis showed a consistent, homogeneous
effect of seven of the eight tSNPs associated with serum
adiponectin in the BHS cohort (q<0.05). tSNP rs1063537
(and rs2241766 via strong LD) showed significant evi-
dence of heterogeneity (P=0.001), indicating differences
between the cohorts at this marker. Two additional
tSNPs (rs10937273 and rs822395) were also associated
with serum adiponectin in the meta-analysis of the three
combined cohorts. Carriage of the minor alleles at
rs12637534, rs1648707 and rs17366568 was associated
with lower serum adiponectin levels (P<1×10-5), while
the minor alleles at rs10937273, rs16861209, rs822395,
rs3774261, rs6444175 and rs17373414 was associated
with higher serum adiponectin levels (P≤0.02).
To determine which of the 9 SNPs identified in the
meta-analysis independently contribute to adiponectin
variation, we conducted a conditional regression analysis
in all three cohorts; this analysis showed that 3 of the top
9 SNPs were independently associated with adiponectin
levels in the BHS, including rs12637534, rs16861209 and
rs17366568. Similar results were found in the other two
studies, where both rs16861209 and rs17366568 remainedsignificant in FDS, while rs16861209, rs17366568 and
rs1648707 were significant in CUDAS.
Associations of haplotypes with serum adiponectin
Associations between the most frequent haplotypes and
serum adiponectin were analysed after correcting for
age, gender and BMI in each cohort (data not shown).
All cohorts were combined and meta-analysis performed
on these haplotypes using random effects modelling
(Table 3). The haplotype-based associations were con-
sistent with the results from the single tSNP analyses.
In block 1, five common haplotypes were observed
that significantly affected serum adiponectin. Haplotypes
carrying the major allele at rs12637534 and rs1648707
(A-A) were found to increase serum adiponectin (all
P≤9.20×10-3), with the exception of the GAAT haplotype
where one copy was associated with decreased serum
adiponectin concentrations (P=0.03). The opposite was
true for carriage of the minor allele at each of these tSNPs,
with one copy of GGCG associated with a significantly
decreased serum adiponectin (P=8.22×10-7). One haplo-
type, GACG, carrying the major allele at rs12637534 (A)
and minor allele at rs1648707 (C), was also associated
with a decreased serum adiponectin, suggesting that the
effect of rs1648707 may be stronger than rs12637534. This
seems likely given the lower minor allele frequency of
rs12637534 compared to rs1648707 (8% vs 34%).
Table 2 Meta-analysis of the association between ADIPOQ SNPs and serum adiponectin in our combined cohort of
3,431 individuals
SNP Number of individuals β (95% CI) P-value P-value (heterogeneity)
rs10937273
GA 1576 0.0004 (−0.041, 0.041) 0.98 0.63
AA 577 0.081 (0.027, 0.134) 3.30E-03 0.83
rs12637534
AG 481 −0.147 (−0.209, -0.085) 3.39E-06 0.26
GG 18 0.076 (−0.171, 0.323) 0.55 0.63
rs1648707
AC 1473 −0.090 (−0.129, -0.050) 8.06E-06 0.44
CC 392 −0.192 (−0.252, -0.131) 5.41E-10 0.80
rs860291
CT 767 0.028 (−0.017, 0.072) 0.22 0.61
TT 50 0.089 (−0.064, 0.243) 0.25 0.97
rs16861209
CA 530 0.246 (0.179, 0.313) 8.14E-13 0.17
AA 27 0.337 (0.129, 0.545) 1.50E-03 0.61
rs822395
AC 1465 0.052 (0.007, 0.098) 0.02 0.28
CC 404 0.069 (0.009, 0.129) 0.03 0.88
rs822396
AG 998 0.002 (−0.039, 0.043) 0.92 0.90
GG 129 0.010 (−0.087, 0.108) 0.84 0.49
rs12495941
GT 1500 0.006 (−0.034, 0.046) 0.77 0.41
TT 386 0.056 (−0.035, 0.148) 0.23 0.11
rs17366568
GA 691 −0.146 (−0.205, -0.087) 1.22E-06 0.19
AA 41 −0.370 (−0.543, -0.197) 2.72E-05 0.34
rs3821799
CT 1573 0.024 (−0.034, 0.082) 0.42 0.16
TT 685 0.051 (−0.002, 0.104) 0.06 0.52
rs3774261
GA 1502 0.060 (0.019, 0.010) 3.80E-03 0.63
AA 517 0.176 (0.120, 0.231) 4.98E-10 0.60
rs1063537
CT 659 0.026 (−0.045, 0.096) 0.48 0.11
TT 47 0.233 (−0.203, 0.669) 0.29 0.001
rs6444175
GA 1300 0.067 (0.028, 0.106) 7.00E-04 0.45
AA 229 0.180 (0.105, 0.255) 2.40E-06 0.74
rs7628649
CT 656 0.031 (−0.015, 0.077) 0.19 0.51
TT 47 0.188 (−0.082, 0.458) 0.17 0.05
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Table 2 Meta-analysis of the association between ADIPOQ SNPs and serum adiponectin in our combined cohort of
3,431 individuals (Continued)
rs17373414
CT 654 0.116 (0.069, 0.163) 1.64E-06 0.35
TT 35 −0.004 (−0.186, 0.179) 0.97 0.39
rs9860747
CT 871 0.018 (−0.024, 0.061) 0.40 0.67
TT 90 0.073 (−0.042, 0.187) 0.21 0.43
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carrying the minor alleles at rs16861209 (A) and rs822395
(C) (both associated with a higher serum adiponectin)
was found to be significantly associated with serum
adiponectin (P=5.11×10-15). This haplotype was found to
be significant in each cohort and explained 2.3% of the
variation in levels in BHS, 2.0% in CUDAS and 0.7% in
FDS. Conversely, three haplotypes carrying the major
allele at rs16861209 (associated with a lower serum
adiponectin) were found to be significantly associated with
a decreased serum adiponectin (all P≤3.11×10-2).
Two haplotypes in block 3 were significantly
associated with serum adiponectin in the meta-analysis,
and in each individual cohort. The TTACA haplotype
(frequency ~25%) was associated with increased levels
and TTGCG (frequency ~6%) with decreased levels
(P≤4×10-4 and P≤2.87×10-12, respectively). The TTACA
haplotype carries the minor allele (A allele) at both
rs3774261 and rs6444175 that was shown in the single
tSNP analyses to be associated with increased serum
adiponectin, while TTGCG carries the major allele at
each of these tSNPs and has the opposite effect on
levels, again showing consistency between single tSNP
and haplotype analysis. This haplotype accounted for
2.3% of the variation in levels in BHS, 0.7% in CUDAS
and 0.6% in FDS. The more common TTACA haplotype
only accounted for between 0.3 and 0.7% of the variation
in levels across all three cohorts.
In all haplotype blocks, the single SNPs tagging the
block accounted for the same, or slightly more of the
variation in adiponectin levels than the haplotype block
itself (difference of between 0–0.8% between the tSNPs
and the haplotypes).
Association of tSNPs with T2D, lnHOMA-IR and MetS
No significant associations were detected between genetic
variants in ADIPOQ, or ADIPOR1/R2, and lnHOMA-IR
or MetS in any cohort after correction for age, gender and
BMI. We also found no association between the ADIPOQ
and ADIPOR1/R2 genetic variants and T2D in the case:
control analysis (results not shown).
There was a significant association between the allele score
of the top nine SNPs and T2D in the case–control studywithout adjusting for adiponectin levels (OR=0.94, 95% CI=
(0.91,0.98), P=0.0015) and this association strengthened after
adjusting for adiponectin levels (OR=0.92, 95% CI=(0.89,
0.96), P=2.43×10-5). The allele score of the 3 independent
SNPs; rs12637534, rs16861209, rs17366568, were signi-
ficantly associated with T2D only after adjusting for
adiponectin levels (OR=0.86, 95%CI=(0.75, 0.99), P=0.0134).
Discussion
The present study reports associations between total
serum adiponectin concentrations and a range of genetic
variations and haplotypes in the adiponectin gene
(ADIPOQ) and genes for adiponectin receptors 1 and 2
(ADIPOR1/R2) in three independent European-Australian
population-based cohorts. Several genetic variants in
ADIPOQ, but not ADIPOR1/R2, were associated with
serum adiponectin. These associations were consistent
across the three cohorts and showed similar results for
tSNP and haplotype-based analysis. After adjusting for
age, gender, and BMI, variants in the ADIPOQ gene
accounted for only 3.9% of the variation in serum adipo-
nectin in the combined general population cohorts and
1.7% in the diabetic sample. There was also no association
between tSNPs or haplotypes of ADIPOQ, and ADIPOR1/
R2 with T2D, insulin resistance assessed by lnHOMA-IR,
or MetS.
This relatively large study confirms that ADIPOQ tSNPs
are significantly associated with serum adiponectin.
We found the minor alleles at rs12637534, rs1648707/
rs6810075 and rs17366568 to be associated with lower
serum adiponectin concentration (P<1×10-5), while
the minor alleles at rs10937273, rs16861209/rs822387,
rs822395, rs3774261, rs6444175 and rs17373414 were
associated with higher levels (P≤0.02). These associations
and their direction are consistent with the hypothesis that
circulating adiponectin levels are in part determined by
genetic influences [3-7,9,10,29-31].
We failed to replicate previous findings in the literature
for ADIPOQ SNPs rs2241766, rs1063537 and rs3821799
that have been reported in two large GWAS [3,31], but
not supported by other studies [4,8]. In addition, there
were three tSNPs (rs266729, rs62625753 and rs17366743)
reported as associated with serum adiponectin that did
Table 3 Meta-analysis of the association between ADIPOQ haplotypes and serum adiponectin in our combined cohort
of 3,431 individuals
Block Haplotype and copy number β (95% CI) P-value P-value (heterogeneity)
1 AAAG
1 0.001 (−0.041, 0.043) 0.96 0.67
2 0.081 (0.026, 0.135) 3.70E-03 0.74
GACG
1 −0.071 (−0.110, -0.032) 4.00E-04 0.79
2 −0.109 (−0.183, -0.035) 3.70E-03 0.61
GAAT
1 −0.047 (−0.089, -0.005) 3.00E-02 0.62
2 0.026 (−0.099, 0.152) 0.68 0.85
GAAG
1 0.219 (0.142, 0.296) 2.55E-08 0.11
2 0.280 (0.070, 0.490) 9.20E-03 0.89
GGCG
1 −0.152 (−0.231, -0.092) 8.22E-07 0.28
2 0.051 (−0.188, 0.291) 0.67 0.60
2 TCCTAAT
1 0.007 (−0.036, 0.049) 0.76 0.34
2 0.052 (−0.048, 0.153) 0.31 0.08
TCCTAAG
1 −0.069 (−0.108, 0.030) 6.00E-04 0.54
2 −0.115 (−0.183, -0.046) 1.00E-03 0.64
TTCCCGG
1 0.026 (−0.021, 0.073) 0.28 0.73
2 0.122 (−0.035, 0.278) 0.13 0.96
CCATCAG
1 0.244 (0.183, 0.305) 5.11E-15 0.29
2 0.301 (0.079, 0.523) 7.80E-03 0.88
TCCTCAG
1 −0.156 (−0.228, -0.084) 2.42E-05 0.22
2 −0.402 (−0.066, -0.146) 2.10E-03 0.74
TCCCCGG
1 −0.067 (−0.129, -0.006) 3.11E-02 0.37
2 0.088 (−0.217, 0.393) 0.57 0.45
3 TCGCG
1 −0.030 (−0.081, 0.022) 0.25 0.34
2 −0.044 (−0.096, 0.008) 0.09 0.44
TTACA
1 0.071 (0.032, 0.111) 4.00E-04 0.57
2 0.190 (0.114, 0.267) 1.01E-06 0.88
GTATG
1 0.022 (−0.049, 0.094) 0.54 0.12
2 0.220 (−0.207, 0.647) 0.31 0.001
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in the present study. LD data available from Heid et al. [3]
show that rs266729 is correlated (r2>0.60, D’>0.80) with
tSNPs which were significant in our study (rs6810075,
rs182052 and rs1648707).
The lack of replication of the association between
adiponectin levels and SNPs previously identified in GWAS
is intriguing. As several rare population-specific coding
variants have been reported to be strongly associated with
adiponectin level [6,32,33] One possible explanation for the
observed discrepancies may be due to synthetic associations
i.e. the fact that population-specific rare variants are in par-
tial linkage disequilibrium with common variants [34].
In the present study, the significantly associated tSNPs
were located across all regions of the gene, including the
promoter, exonic, intronic and 30-untranslated regions.
Interestingly, all of the tSNPs downstream of exon 2
were associated with an increased serum adiponectin.
We observed no association between ADIPOR1/R2
variants and serum adiponectin which is consistent with
most other studies [14,35-37]. Recent genome-wide stud-
ies have identified variants in a third adiponectin receptor,
T-cadherin, that affect circulating adiponectin [2,4,38,39].
T-cadherin, encoded by CDH13, is a receptor for hexa-
meric and high-molecular-weight adiponectin, but not for
the trimeric or globular species as measured in the present
study. Nevertheless, variants in CDH13 warrant further
investigation.
Despite the fact that ADIPOQ variants are associated
with a modest amount of variance in total serum
adiponectin (<5%), interventions aimed at the encoded
protein may affect secreted adiponectin to a much
greater extent. Indeed, the thiazolidinediones have been
shown to increase circulating adiponectin 2–2.5 fold in
patients with diabetes, although the exact mechanism of
action remains unknown. Other population studies have
reported similar quantitatively small effects of ADIPOQ
SNPs, and show that there are a large number of SNPs
contributing independently to the variation [3,7,40]. A
recent large multiethnic GWAS identified ten new loci,
in addition to ADIPOQ and CDH13, that affect circulat-
ing adiponectin, but the combined multi-SNP genotypic
risk score only explained 5% of the variance in serum
adiponectin [31]. The high heritability estimates for
adiponectin may be explained by as-yet undiscoveredrare variants with strong effects, additional unknown
common loci with small effects, epigenetic mechanisms,
or by copy number variations (CNVs). ADIPOQ contains
a high number of CNVs and the effect of these on circu-
lating adiponectin is unknown. Complete sequencing of
the ADIPOQ locus has been performed in a large popu-
lation where seven SNPs were shown to influence adipo-
nectin levels but the authors found no evidence of an
association between these SNPs and T2D in a diabetic
case control study [33].
Recently, studies have identified rare population-specific
mutations that account for 17% of the variance in serum
adiponectin [32,41]. Further analysis of gene-gene and
gene-environment interactions may explain the remaining
heritability.
Despite putative effects of the adiponectin receptors on
tissue adiponectin activity, we found no evidence that
tSNPs in ADIPOQ, or ADIPOR1/R2 were associated
with either insulin resistance, or MetS. This supports the
findings of two other studies [5,33]. However, we did find
a significant association between the allele score of the top
nine SNPs and T2D in the case–control study without
adjusting for adiponectin levels. Multi-SNP genotypic risk
score for adiponectin-decreasing alleles has been associated
with BMI, WHR, fasting insulin, HOMA-IR, 2-hour post
OGTT glucose, T2D, triglycerides and HDL-cholesterol
[31]. In the current study a post-hoc analysis revealed that
adjusting for adiponectin levels strengthened the associ-
ation with 3 independent SNPs, rs12637534, rs16861209,
rs17366568 and T2D. The strengthening of this association
provides strong evidence that the genetic determinants of
adiponectin levels are shared with T2D using a Mendelian
randomisation approach [13].
There have been numerous studies investigating the as-
sociation of adiponectin gene and related polymorphisms
with T2D. Two recent large meta-analyses showed that
the G vs C allele of rs266729 might be a risk factor for
T2D [42,43], while the rs17300539 A allele was shown to
be a risk factor only in European Caucasians [43]. The lat-
ter SNP is in complete LD with rs16861209 that we have
identified in our Caucasian populations.
The limitations of this study include the use of a sin-
gle baseline serum adiponectin measurement which
may not fully characterise long-term adiponectin expos-
ure and effects. Nevertheless, other prospective studies
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ments, on average one year apart, reported high intra-
class correlations above 0.71 [35,44], indicating high
reproducibility of serum adiponectin levels. In the
present study, total serum adiponectin levels were
measured, whereas recent evidence suggests that the
high molecular-weight form of adiponectin, rather than
the low molecular-weight forms, may be the bioactive
protein [45].
Conclusions
In summary, we have comprehensively analysed the ge-
netic variants and haplotypes of ADIPOQ and its two re-
ceptor genes using a tagSNP approach in two general
populations and a diabetic cohort, in total comprising
3,322 well phenotyped subjects. We found that age, gen-
der and BMI accounted for approximately one-third of
the variation in serum adiponectin in the general popula-
tion cohorts and just over one-fifth in a diabetic popula-
tion. Variants in the ADIPOQ gene accounted for <5% of
the variation in serum adiponectin and genetic variants in
ADIPOQ and its receptors does not appear to contribute
to the risk of insulin resistance or metabolic syndrome.
However, a multi-SNP genotypic risk score for ADIPOQ
did associate with T2D independent of adiponectin levels.
The factors that underlie the majority of the variation in
serum adiponectin remain unknown, but given the poten-
tial beneficial effects of this adipokine, merit further study.
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